DS-1103a + T-DXd
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Breast Cancer
Trial Timeline
May 30, 2023 → Jun 30, 2026
NCT ID
NCT05765851About DS-1103a + T-DXd
DS-1103a + T-DXd is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT05765851. Target conditions include Advanced Solid Tumor, Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05765851 | Phase 1 | Active |
Competing Products
20 competing products in Advanced Solid Tumor